

Gunnar Tomasson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3256293/publications.pdf>

Version: 2024-02-01

34
papers

1,104
citations

516710

16
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

1572
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile: COVIDMENT: COVID-19 cohorts on mental health across six nations. <i>International Journal of Epidemiology</i> , 2022, 51, e108-e122.	1.9	16
2	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-associated Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	2.1	6
3	Adverse childhood experiences and resilience among adult women: A population-based study. <i>ELife</i> , 2022, 11, .	6.0	16
4	Association between adverse childhood experiences and premenstrual disorders: a cross-sectional analysis of 11,973 women. <i>BMC Medicine</i> , 2022, 20, 60.	5.5	9
5	Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review. <i>Rheumatology</i> , 2022, 61, 4603-4618.	1.9	7
6	Sleep disturbances among women in a Subarctic region: a nationwide study. <i>Sleep</i> , 2022, 45, .	1.1	2
7	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152021.	3.4	2
8	Illness severity and risk of mental morbidities among patients recovering from COVID-19: a cross-sectional study in the Icelandic population. <i>BMJ Open</i> , 2021, 11, e049967.	1.9	6
9	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1134-1138.	3.4	4
10	Patients in need of comprehensive geriatric assessment: The utility of the InterRAI emergency department screener. <i>International Emergency Nursing</i> , 2021, 54, 100943.	1.5	3
11	Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1370-1377.	3.4	3
12	Suicide rates in Iceland before and after the 2008 Global Recession: a nationwide population-based study. <i>European Journal of Public Health</i> , 2020, 30, 1102-1108.	0.3	8
13	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1314-1325.	3.4	17
14	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1198-1201.	2.0	24
15	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
16	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. <i>Journal of Rheumatology</i> , 2019, 46, 1415-1420.	2.0	7
17	Long-lasting improvements in health-related quality of life among women with chronic pain, following multidisciplinary rehabilitation. <i>Disability and Rehabilitation</i> , 2018, 40, 1764-1772.	1.8	10
18	Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology International</i> , 2018, 38, 675-682.	3.0	40

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 17-34.	1.2	24
20	The association between different traumatic life events and suicidality. <i>HÅrre Utbildning</i> , 2018, 9, 1510279.	3.0	41
21	Association of Stress-Related Disorders With Subsequent Autoimmune Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2388.	7.4	243
22	Infections and the risk of incident giant cell arteritis: a population-based, case-control study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1031-1035.	0.9	51
23	Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 176-184.	5.6	22
24	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1933-1937.	2.0	33
25	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2017, 44, 84-90.	2.0	43
26	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1529-1535.	2.0	25
27	Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population. <i>Journal of Rheumatology</i> , 2016, 43, 1553-1558.	2.0	38
28	Health-related quality of life improvements among women with chronic pain: comparison of two multidisciplinary interventions. <i>Disability and Rehabilitation</i> , 2016, 38, 828-836.	1.8	15
29	Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 38-44.	4.3	3
30	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process. <i>Journal of Rheumatology</i> , 2015, 42, 2204-2209.	2.0	22
31	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2465-2469.	2.0	33
32	Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2014, 66, 428-432.	5.6	28
33	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1329-1334.	0.9	218
34	Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda. <i>Journal of Rheumatology</i> , 2011, 38, 1471-1479.	2.0	79